NCT05077527 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Status RECRUITING Phase PHASE1
NCT05069935 FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT05052528 Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE1
NCT05049473 Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. Status UNKNOWN Phase PHASE2
NCT05040568 A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) Status COMPLETED Phase PHASE1
NCT05035407 T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers Status TERMINATED Phase PHASE1
NCT05032820 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Status COMPLETED Phase PHASE2
NCT05032183 Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT05020860 Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer Status RECRUITING Phase PHASE2
NCT05008224 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) Status COMPLETED Phase PHASE2
NCT05005299 Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Status RECRUITING Phase PHASE1
NCT05003895 GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies Status RECRUITING Phase PHASE1
NCT05000450 Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma Status TERMINATED Phase PHASE1/PHASE2
NCT04994132 A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04989803 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04978584 Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04974996 A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) Status WITHDRAWN Phase PHASE1